10-Q: Kalaris Therapeutics Bolsters Cash, Advances TH103 Trials

Kalaris Therapeutics, a clinical-stage biopharmaceutical company, reported Q3 2025 financial results, highlighting progress in its TH103 clinical trials and a strengthened cash position following its merger with AlloVir.

Summary

• Net loss for the nine months ended September 30, 2025, was $33.4 million, a decrease from $47.1 million for the same period in 2024.
• Net loss for the three months ended September 30, 2025, was $11.894 million, down from $38.084 million in the prior year's quarter.
• Cash, cash equivalents, and short-term investments totaled $77.0 million as of September 30, 2025, significantly up from $1.639 million as of December 31, 2024.
• The company's accumulated deficit reached $150.0 million as of September 30, 2025.
• The merger with AlloVir, Inc. closed on March 18, 2025, with Legacy Kalaris deemed the accounting acquirer, bringing approximately $102.1 million in cash and cash equivalents.
• The lead product candidate, TH103, a novel anti-VEGF drug for retinal diseases, is in ongoing Phase 1a and newly initiated Phase 1b/2 clinical trials for neovascular Age-related Macular Degeneration (nAMD).
• Initial clinical data from the Phase 1a trial is expected by year-end 2025, and from the Phase 1b/2 trial in the second half of 2026.
• Material weaknesses in internal control over financial reporting identified as of December 31, 2024, remain unremediated as of September 30, 2025, though remediation efforts are underway.
• Management expects existing cash resources to fund operating expenses and capital expenditure requirements into 2027.

Sentiment

Score: 6

Explanation: While the company continues to incur significant losses and faces substantial risks inherent in early-stage biopharmaceutical development, the successful merger with AlloVir has significantly bolstered its cash position, extending its cash runway into 2027. This provides crucial funding for advancing its lead product candidate, TH103, through ongoing clinical trials. The reduction in net loss compared to the prior year is also a positive sign, although operational cash burn remains high. The material weaknesses in internal controls are a concern, but remediation efforts are underway.

Positives

• Cash, cash equivalents, and short-term investments significantly increased to $77.0 million as of September 30, 2025, primarily due to the $102.1 million cash acquired from the AlloVir merger.
• Net loss for the nine months ended September 30, 2025, decreased to $33.4 million from $47.1 million in the prior year, indicating improved financial performance.
• Net loss for the three months ended September 30, 2025, decreased to $11.894 million from $38.084 million in the prior year's quarter.
• Progress in clinical development with the ongoing Phase 1a and newly initiated Phase 1b/2 clinical trials for TH103 in neovascular Age-related Macular Degeneration (nAMD).
• Preclinical studies showed TH103 had more anti-VEGF activity and longer duration of activity compared to aflibercept, a current market leader.
• Management expects existing cash to fund operating expenses and capital expenditure requirements into 2027, providing a longer runway.
• A gain of $0.4 million was recognized from the change in fair value of tranche liability for the nine months ended September 30, 2025.
• A gain of $1.2 million was recognized from the change in fair value of derivative liabilities for the nine months ended September 30, 2025.
• Key management positions (CFO, Chief Accounting Officer, Controller) have been filled or assumed by experienced personnel, and a new audit committee chair appointed, as part of remediation efforts for internal control weaknesses.

Negatives

• The company continues to incur significant operating losses and negative cash flows from operations, with $31.3 million used in operating activities for the nine months ended September 30, 2025.
• An accumulated deficit of $150.0 million as of September 30, 2025, highlights a history of unprofitability.
• Material weaknesses in internal control over financial reporting identified as of December 31, 2024, remain unremediated as of September 30, 2025, posing a risk of financial misstatements.
• No revenue has been generated from product sales since inception, and profitability is not expected for the foreseeable future.
• The business is heavily dependent on the successful development and commercialization of a single lead product candidate, TH103, which is still in early-stage clinical development.
• Substantial additional funding will be required beyond 2027 to continue product development and operations.
• The company incurred approximately $5.4 million in transaction costs related to the Merger, recorded as a reduction to additional paid-in capital.
• Ongoing litigation related to the Merger, with two complaints filed by purported AlloVir stockholders alleging misrepresentation/omission in the proxy statement/prospectus.

Risks

• Incurred significant losses since inception and expects to continue incurring significant expenses and operating losses for the foreseeable future, and may never achieve or maintain profitability.
• Never generated revenue from product sales and may never achieve or maintain profitability.
• Heavily dependent on the success of lead product candidate, TH103; if it does not receive marketing approval or is not successfully commercialized, or if there is significant delay, business will be harmed.
• Will need substantial additional funding for continuing operations; inability to raise capital when needed or on acceptable terms could force delays, reductions, or elimination of product development programs or commercialization efforts.
• Identified material weaknesses in internal control over financial reporting as of December 31, 2024, which remain unremediated as of September 30, 2025, potentially leading to material misstatements.
• Early in development efforts; inability to commercialize TH103 or any product candidate or significant delays will materially harm the business.
• Results of early-stage clinical trials and preclinical studies may not be predictive of future results; initial success may not be indicative of results in later stage trials.
• Delays or difficulties in patient enrollment for clinical trials could delay or prevent marketing approvals.
• Even if TH103 receives marketing approval, failure to achieve market acceptance by physicians, patients, and third-party payors could limit commercial success.
• Reliance on third parties to conduct clinical trials; unsatisfactory performance could delay or prevent marketing approval or commercialization.
• Inability to obtain and maintain sufficient intellectual property protection or if the scope is not broad enough, competitors could develop similar products.
• Regulatory approval process is expensive, time-consuming, and uncertain; may not receive approvals in a timely manner or at all.
• Market price of common stock has been and is expected to continue to be volatile.
• May be unable to successfully integrate the businesses of AlloVir and Legacy Kalaris and realize anticipated benefits of the Merger.
• Incurs additional costs and increased demands upon management due to complying with public company laws and regulations.
• Uncertainty whether an active, liquid, and orderly trading market will develop for common stock.
• Executive officers, directors, and principal stockholder (Samsara LP) have ability to control or significantly influence matters submitted to stockholders.
• Samsara LP beneficially owns >50% of capital stock, making the company a controlled company under Nasdaq rules, relying on exemptions from certain corporate governance requirements.
• Ability to use net operating loss carryforwards (NOLs) and research and development tax credit carryforwards may be subject to limitations due to ownership changes.
• Dose limiting toxicities, serious adverse events, undesirable side effects, or unexpected characteristics identified during development could lead to abandonment or limitation of further clinical development.
• If TH103 or any other product candidate receives marketing approval and later found less effective or causes undesirable side effects, ability to market could be compromised.
• May expend limited resources on a particular product candidate/indication and fail to capitalize on more profitable ones.
• Manufacturing biologics is complex; manufacturing problems could result in delays.
• Reliance on single-source suppliers for certain materials and components.
• Collaborations with third parties may not be successful.
• Acquisitions or in-license transactions could disrupt business, cause dilution, or reduce financial resources.
• Inability to protect confidentiality of trade secrets.
• Subject to claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of former employers or other third parties.
• Trademarks and trade names may not be adequately protected.
• Intellectual property rights do not necessarily address all potential threats to competitive advantage.
• Failure to comply with obligations under license, collaboration, or other agreements could lead to termination and loss of intellectual property rights.
• Subject to stringent privacy laws, information security laws, regulations, policies, and contractual obligations related to data privacy and security; failure to comply could lead to fines and penalties.
• Changes in and uncertainty surrounding U.S. trade policy could have material adverse impact.
• Future success depends on ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel.
• May encounter difficulties in managing growth, which could disrupt operations.
• Internal computer systems, or those of collaborators, vendors, etc., may fail or suffer security breaches.
• Employees, independent contractors, etc., may engage in misconduct or other improper activities.
• Changes in tax laws or their implementation/interpretation could adversely affect business and financial condition.
• Anti-takeover provisions could delay or prevent a change of control.
• Bylaws designate specific courts as sole and exclusive forum for certain actions.
• Will no longer qualify as an emerging growth company as of December 31, 2025.
• Transfers of securities utilizing Rule 144 may be limited due to prior shell company status.
• Future sales and issuances of common stock could result in additional dilution.

Future Outlook

The company expects to continue incurring substantial losses for the foreseeable future and does not anticipate generating revenue from commercial product sales until successful development and regulatory approval of its product candidates. Expenses are projected to increase significantly with ongoing clinical trials for TH103, future preclinical studies, and potential commercialization efforts. Initial clinical data from the Phase 1a trial is expected by year-end 2025, and from the Phase 1b/2 trial in the second half of 2026. The company plans to expand TH103 development into other retinal diseases like DME, DR, and RVO. Existing cash resources are expected to fund operations into 2027, but substantial additional financing will be required thereafter.

Management Comments

• Our management expects that our cash, cash equivalents and short-term investments will be sufficient to fund our operating expenses and capital expenditure requirements for at least twelve months from the issuance date of these condensed consolidated financial statements.
• We expect to continue to incur substantial losses for the foreseeable future, including costs associated with operating as a public company.
• We do not expect to generate any revenue from commercial product sales unless and until we successfully complete development and obtain regulatory approval for our product candidate.
• Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of our product candidate, which may never occur.
• We may never achieve or maintain profitability.
• Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations.

Industry Context

The biopharmaceutical industry, particularly in retinal diseases, is characterized by intense investment and rapid technological advancements. Kalaris Therapeutics' lead candidate, TH103, is an anti-VEGF drug entering a competitive market with established leaders like aflibercept and brolucizumab, as well as several biosimilars and emerging gene therapies. The regulatory environment is dynamic, with new EU clinical trial regulations and ongoing uncertainty in US FDA guidance due to executive orders and litigation, particularly concerning diversity action plans and drug pricing. Macroeconomic factors such as inflation, interest rate fluctuations, and geopolitical tensions are also impacting capital access and operational costs across the industry.

Comparison to Industry Standards

• TH103 showed more anti-VEGF activity and longer duration of activity compared to aflibercept, the current global market-leading anti-VEGF agent, in head-to-head preclinical studies.
• The company faces substantial competition from large pharmaceutical companies like Novartis AG, Regeneron Pharmaceuticals, Inc., AbbVie Inc., and F. Hoffmann-La Roche AG, which have commercialized or are developing treatments for nAMD.
• Several companies have received FDA approval for biosimilars to treat nAMD, including Samsung Bioepis Co., Ltd. and Biogen Inc. (Byooviz, Opuviz), Coherus BioSciences, Inc. (Cimerli), Formycon AG (Ahzantive), Sandoz Group AG (Enzeevu), Mylan Laboratories Inc. and Biocon Biologics Limited (Yesafili), and Amgen Inc. (Pavblu), which may increase pricing pressure.
• Emerging biopharmaceutical companies such as 4D Molecular Therapeutics, Inc., Adverum Biotechnologies, Inc., RegenexBio Inc., Eyepoint Pharmaceuticals, Inc., and Ocular Therapeutix, Inc. are advancing anti-VEGF gene therapy candidates and sustained-release inhibitors for nAMD and DME, indicating a highly active competitive landscape.

Management Changes

Corporate Governance

Legal Proceedings

• Securities Class Action (Zerbato v. AlloVir, Inc. et al., No. 1:24-cv-10152 (D. Mass.)): Filed January 19, 2024, alleging false and misleading statements related to AlloVir's Phase 3 studies of posoleucel. Settled for $1.0 million on April 14, 2025, and dismissed with prejudice on July 30, 2025.
• Derivative Lawsuit (Lister v. Brainard et al., No. 1:24-cv-12658 (D. Mass.)): Filed October 21, 2024, against AlloVir officers and directors, alleging breach of fiduciary duties and other claims. Voluntarily dismissed without prejudice on August 1, 2025.
• Merger-Related Litigation (Keller v. AlloVir, Inc. et al., No. 650989/2025 (N.Y. Sup. Ct. Feb. 20, 2025), and Morgan v. AlloVir, Inc. et al., No. 650965/2025 (N.Y. Sup. Ct. Feb. 19, 2025)): Two individual actions filed by purported AlloVir stockholders alleging misrepresentation and/or omission of material information in the proxy statement/prospectus for the merger. The company denies the allegations.

Related Party Transactions

• Samsara BioCapital L.P. and its affiliates (Samsara) is the company's majority stockholder and a related party.
• Samsara provided in-kind research and development and general and administrative services to Legacy Kalaris since inception, ceasing in July 2024.
• Samsara provides general and administrative services for cash consideration (accounting, controllership, human resources, executive assistance) under a Business Services Agreement (BSA) since April 2022. The company recognized $0.1 million for each of the three months ended September 30, 2025 and 2024, and $0.3 million and $0.1 million for the nine months ended September 30, 2025 and 2024, respectively, as general and administrative expenses.
• In July 2024, the company entered into a Royalty Agreement with Samsara, redeeming 10,080 shares of common stock in exchange for a low single-digit percentage tiered royalty on net sales of products developed using UCSD licensed technology. A long-term liability of $32.1 million was recorded for this obligation.
• The company issued convertible promissory notes (2024 Note, 2024 Bridge Notes, 2025 Bridge Notes) to Samsara and other investors. The 2024 Note ($10.0 million) and 2024 Bridge Notes ($10.0 million) were converted into common stock in connection with the Merger. The 2025 Bridge Notes ($3.75 million) were converted into Series B-2 Stock.
• Samsara LP controlled approximately 61.21% of the voting power of the company's capital stock as of September 30, 2025.

Stakeholder Impact

• Shareholders: Experience potential dilution from future equity raises and equity incentive plans. The stock price is expected to remain volatile. Samsara LP's majority ownership grants it significant influence over corporate decisions. Potential for long-term value creation if TH103 succeeds, but also significant risk due to ongoing losses and development uncertainties.
• Employees: Benefit from continued investment in R&D and G&A, including personnel costs and stock-based compensation. Changes in management and remediation efforts for internal controls may impact roles and responsibilities.
• Customers (future patients): Potential for a novel anti-VEGF drug (TH103) that could offer longer-lasting and increased activity for prevalent retinal diseases, addressing unmet medical needs.
• Suppliers/Vendors (CDMOs, CROs): Continued reliance on third parties for manufacturing and clinical trials ensures ongoing business for these partners, but performance failures could impact the company.
• Creditors: Convertible promissory notes have been converted, reducing direct debt. The royalty obligation to Samsara is a long-term liability. The company's significantly improved cash position provides a stronger financial buffer, potentially reducing immediate credit risk.

Next Steps

• Report initial clinical data, including safety, preliminary efficacy, and pharmacokinetics, from the Phase 1a clinical trial of TH103 by year-end 2025.
• Report initial clinical data from the Phase 1b/2 multiple ascending dose clinical trial of TH103 in the second half of 2026.
• Expand the development of TH103 beyond nAMD into other prevalent VEGF-mediated retinal diseases, such as Diabetic Macular Edema (DME), diabetic retinopathy (DR), and Retinal Vein Occlusion (RVO).
• Continue to implement and improve managerial, operational, and financial systems to manage anticipated future growth.
• Continue to recruit and train additional qualified personnel, including addressing material weaknesses in internal control over financial reporting.
• Monitor expenses and raise additional capital through equity and debt financings, strategic alliances, and licensing arrangements to fund operations beyond 2027.

Key Dates

Recommendation

Kalaris Therapeutics has significantly strengthened its balance sheet through the merger with AlloVir, providing a cash runway into 2027, which is critical for an early-stage biopharmaceutical company. The progress of TH103 into Phase 1b/2 trials and the preclinical data suggesting superiority to aflibercept are positive indicators for its lead candidate. However, the company remains pre-revenue, highly dependent on a single asset, and continues to incur substantial operating losses. The identified material weaknesses in internal controls, while being addressed, add a layer of operational risk. The competitive landscape for retinal diseases is intense, with established players and emerging biosimilars. Given the early stage of development for TH103 and the inherent risks of clinical trials, a 'hold' recommendation is appropriate. Investors should monitor the upcoming Phase 1a data by year-end 2025 and Phase 1b/2 data in H2 2026, as well as the remediation of internal control weaknesses, before considering further investment.

Keywords

Biopharmaceutical, Retinal diseases, TH103, nAMD, Clinical trials, Merger, AlloVir, Financial results, Drug development, Biotech, Ophthalmology, VEGF inhibitor, Internal controls, Capital raise, Samsara BioCapital, 10-Q